Stockreport

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of B [Read more]